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Background: Among American women, 30% of all new cancer diagnoses are of breast cancer 
(BC) and ~25% of these cancers overproduce the growth-promoting tyrosine kinase receptor, 
HER2. Although there are targeted treatments available for HER2-overexpressing BC, this 
disease is associated with poorer prognosis and increased risk of recurrence, making 
identification of new treatment methods crucial. It is well-established that calorie restriction 
(CR), or chronic dietary energy restriction by ~30%, has significant tumor suppressive effects 
across cancer subtypes and has potential to be utilized as an adjunctive therapy. This study 
investigates the mechanisms by which CR decreases HER2-overexpressing BC progression.  
 
Methods: To mimic CR in vitro, murine MMTV-neu cells that overexpress HER2 were treated 
with medias containing reduced serum (1%), reduced glucose (1mM), or reduced serum and 
reduced glucose (1%/1mM) compared to control media (10% serum, 25mM glucose). The 
impact of differential nutrient restriction on MMTV-neu regulatory mechanisms was 
characterized using MTT assays, anchorage independent colony formation assays, cell cycle 
analysis, and apoptosis assays.  To investigate the mechanism of this alteration, western blotting 
analysis of proteins along the PI3K/Akt and Ras/Erk pathways was conducted. The efficacy of 
nutrient restriction as an adjunct therapy was explored by treating cells cultured in restricted 
medias with lapatinib, doxorubicin, and cyclophosphamide.  
 
Results: Serum restriction significantly reduced cellular viability and colony formation of 
MMTV-neu cells and promoted increased cellular apoptosis, and G0/G1 cell cycle arrest. In 
MMTV-neu cells treated with serum restricted medias (1% and 1%/1mM), there was a 
significant decrease in activity of tumor-suppressor protein p21. Both p21 and phospho-21 
expression was decreased with serum restriction, as well as the proportion of phospho-p21 
relative to p21 (p<0.05). Serum and glucose restriction (1%/1mM) increased the sensitivity of 
MMTV-neu cells to treatment with lapatinib and cyclophosphamide, resulting in reduced cellular 
viability (p<0.05).  
 
Conclusion: These results suggest that short-term CR, achieved specifically through serum 
restriction alone or in combination with glucose restriction, is associated with decreased 
phosphorylation and cytoplasmic localization of p21, which may be responsible for modulating 
anti-proliferative activities. This finding is significant because clinical studies have found that 
increased cytoplasmic p21 in HER2-overexpressing BC predicted reduced survival in patients at 
5 years. Utilizing CR in conjunction with existing therapies may prevent or reverse cytoplasmic 
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Obesity and HER2-overexpressing Breast Cancer 
It is well-established that among women with obesity, there is an increased risk of 
developing invasive breast cancer as well having poorer clinical outcomes upon diagnosis (1-5). 
Obesity at time of breast cancer (BC) diagnosis is associated with resistance to therapy, 
increased risk of recurrence, and lower survival rates (6-8). Put in the context of the staggering 
obesity epidemic faced by the U.S. alongside an estimated 252,000 new invasive breast cancer 
cases annually, this association poses a significant public health concern (9,10).  
Given the heterogeneity of this disease, associations between host and tumor 
characteristics must be studied according to molecular subtype of BC. One of the most 
aggressive forms, characterized by amplification and/or overexpression of the human epidermal 
growth factor receptor 2 (HER2) gene, accounts for ~20% of all BC diagnoses and is associated 
with greater tumor burden, higher rates of distal metastases, and worse overall survival rates 
(11,12). Development of therapies that specifically target the HER2/neu receptor have 
demonstrated clinical effectiveness, however, patients with obesity persistently suffer from 
worse outcomes which highlights the importance of elucidating the mechanisms behind this 
obesity cancer link as well as developing novel therapies to ameliorate the burden (13).  
HER2/neu Tumorigenesis  
Over-expression of the HER2 oncogene induces replication stress, leading to a DNA 
damage response and senescence, a non-proliferative but viable state. Alternatively, cells can 
acquire mutations that allow them to bypass this barrier to tumorigenesis, resulting in genomic 
instability and cancer progression (14-16). Through preclinical studies on MMTV-HER2/neu 
transgenic mice, which hyperactively express the HER2 oncogene, the Hursting lab has 
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identified an association between dietary energy balance and breast cancer progression. Mice fed 
a high-fat, obesogenic diet exhibit both an increased frequency and decreased latency of breast 
cancer development, compared to lean, calorie restricted mice (17).  
HER2/neu Signaling Mechanisms 
The HER2 gene is a member of the ErbB receptor tyrosine kinase family. Its associated 
protein, Neu, enhances several kinase signaling cascades upon forming a homo- or heterodimer 
with a ligand-bound epidermal growth factor receptors (EGFR, HER3, HER4). Dimerization 
results in phosphorylation of the intracellular domains of the receptor tyrosine kinases (RTK) 
and leads to recruitment of signaling molecules to initiate kinase pathways (18). These pathways 
can be inappropriately activated in cells that overexpress HER2/neu via autophosphorylation of 
specific tyrosine residues that stabilize signaling through EGFR. This bypasses regulatory 
mechanisms, increasing the oncogenic potential of EGFR and inducing cell transformation and 
tumorigenesis (19).  
The most common HER2 signaling pathways include the phosphatidylinositol-3 kinase 
(PI3K)/Akt and RAS/Mitogen-activated protein kinase (MAPK) cascades (20). In the 
RAS/MAPK cascade, adaptor proteins bind phosphorylated HER2/neu and activate RAS, a 
protein kinase, that initiates a cascade to activate extracellular signal-regulated kinases 1 and 2 
(ERK1/2). ERK interacts with kinases and transcription factors to promote cell growth, 
proliferation, and survival (21). The PI3K/Akt pathway is activated by HER2/RTK dimerization 
and intracellular phosphorylation. The heterodimer PI3K is recruited and activated to 
phosphorylate PIP2 to PIP3. PIP3 induces translocation of Akt to the plasma membrane where it 
regulates proteins involved in cell survival. Through these interactions, the PI3K/Akt activation 
is involved with inhibition of apoptotic pathways, and activation of survival pathways (22).  
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HER2/neu Therapeutic Targets and Resistance  
 The aberrant growth signals promoted by HER2 dimerization are effectively blocked 
with a regimen of therapies (23,24). At present, first-line HER2-positive BC protocol indicates 
use of adjuvant chemotherapy combined with one year of trastuzumab therapy, a humanized 
monoclonal antibody (mAb) directed against the extracellular domain of HER2 that blocks 
signaling ligand-independent HER2 activity(24,25).  In advanced stages of this disease, 
lapatinib, a small molecule dual HER2/1 tyrosine kinase inhibitor is used to inhibit activation of 
the HER2/EGFR pathway by blocking auto-phosphorylation (23,26,27). The action of lapatinib 
has demonstrated effectiveness to induce cellular apoptosis while trastuzumab binding to the 
extracellular HER2 domain may function by sterically modulating the detection of phosphate 
moieties by cytoplasmic signal transduces (28).  
 While the advent of these therapies has dramatically improved overall survival, a 
significant number of patients are unresponsive from the start of treatment, and even more 
acquire resistance over the course of treatment (29,30). The proposed mechanisms of this 
conferred resistance to therapy includes impaired binding of antibody, upregulation of HER2/neu 
downstream signaling pathways, signaling through alternate pathways including IGF1R, c-MET, 
EGFR, and HER2, and failure to trigger immune-mediated destruction of cells (31). Potential 
therapies that reduce trastuzumab resistance include the antibody-drug conjugate, T-DM1, that 
targets HER2 and delivers a cytotoxic agent as well as inhibitors of the PI3K/Akt/mTOR 
pathway (32,33).  
Calorie Restriction as an Adjunctive Therapy  
Another approach that targets signaling molecules along the same PI3K/Akt/mTOR axis 
is the utilization of calorie restriction mimetics in conjunction with chemotherapy. This considers 
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the complex metabolic reprogramming that occurs in malignant cells driven by mutations in 
oncogenes and tumor suppressors (34-36). Long-term calorie restriction (CR), or dietary energy 
restriction by ~30%, has demonstrated tumor suppressive effects across cancer subtypes (37-40). 
This may be mediated in part by enhanced apoptosis within tumors, reduced angiogenesis, and 
alterations in key metabolites and systemic signaling pathways involving insulin-like growth 
factor (IGF)-1 and inflammatory markers (41). Recent studies have found that CR mimetics 
including intermittent / short-term fasting (total caloric restriction ranging from 24 hours to 6 
days), produce similar metabolic benefits modulated by chronic CR, but may be more feasible in 
a clinical setting, potentiating its use as an adjunct therapy in combination with traditional 
chemotherapy (42). Compared to oncogene-driven cells, normal cells suspected to short-term CR 
enter a chemo-protective state characterized by decreased cellular division and increased repair 
pathways, termed the differential stress resistance (DSR) (42-44). This has significant 
implications for reducing the cytotoxicity associated with chemotherapy. Conversely, malignant 
cells are selectively sensitized to chemotherapeutics by short-term CR, called the differential 
stress-sensitization (DSS) where cancer cells are preferentially destroyed by chemotherapy (44). 
While the mechanism is poorly understood, it is likely related to the inability of cancer cells to 
adapt to an environment where nutrients are not available in excess (45). In vitro studies 
demonstrated that breast cancer cells cultured in medium supplemented with serum from fasted 
mice were more susceptible to the chemotherapeutic drugs cyclophosphamide (CP) and 
doxorubicin (DXR), which are commonly used in combination with trastuzumab for HER2-
positive BC treatment (46). These findings were confirmed by in vivo work where mice placed 
on a short-term food starvation regimen (fasting 32 hours prior and 16 hours post-injection with 
water ad libitum) in combination with cisplatin chemotherapy had significantly reduced tumor 
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growth, modulated through hyperactivation of the ataxia-telangectasia mutated (ATM)/human 
homologue of Rad53 (Chk2)-dependent stress response pathway (47). Together, these findings 
demonstrate both the protective and anti-tumorigenic effect of CR mimetics in conjunction with 
chemotherapy and highlight the necessity of identifying the molecular targets that they modulate.  
Impact of Dietary Energy Balance on HER2 Tumorigenesis 
The Hursting laboratory aims to characterize the molecular mechanisms through which 
obesity-related metabolic changes drive tumorigenesis. A recent study that informed this current 
project modeled chronic CR by placing female MMTV-HER2/neu transgenic and wild type FVB 
mice on either a low-fat control regimen (CON, 10 kcal% fat), a 30% CR regimen relative to 
control, or a high-fat diet induced obesity (DIO, 60 kcal% fat) regimen. Compared to the CON 
and DIO groups, calorie restricted mice had decreased adiposity and obesity-related serum 
markers including IGF-1, insulin, leptin, as well as preserved ER and ER expression, 
increased disease-free survival rates, and reduced tumor burden (37). These novel findings 
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Goals and Hypotheses 
This project aims to elucidate the mechanisms through which calorie restriction drives molecular 
and metabolic changes in MMTV-HER2/neu breast cancer cells. 
Aim 1. Determine the impact of nutrient stress on MMTV-HER2/neu BC cell characteristics.  
Short-term calorie restriction was mimicked in vitro to determine the sensitivity of BC 
cancer cells to nutrient stress. Under conditions of nutrient restriction, changes in cancer cell 
viability and proliferative activity as well as regulation of apoptosis and the cell cycle were 
measured. It is hypothesized that MMTV-HER2/neu BC cells will be unable to reprogram 
metabolic pathways in the absence of excess protein and growth factors mimicked by serum 
restriction, which is expected to reduce the viability of cells and alter growth and cell cycle 
maintenance patterns. 
Aim 2. Determine the efficacy of nutrient restriction as an adjunct therapy in conjunction with 
targeted and chemotherapies.  
 MMTV/HER2-neu cells were cultured in nutrient restricted medias and treated with 
either the targeted anti-HER2 therapy, lapatinib, or standard chemotherapeutics, 
cyclophosphamide and doxorubicin, to determine the efficacy of short-term CR as an adjunct 
therapy. It is hypothesized that cancer cells cultured in serum restricted medias will have 
increased sensitivity, and thus reduced viability, in response to treatment with lapatinib, 
doxorubicin, and cyclophosphamide.   
Aim 3. Identify molecular targets altered by nutrient stress in MMTV-HER2/neu BC cells. 
MMTV-HER2/neu breast cancer cells cultured in nutrient restricted medias were 
assessed for changes in key proteins along the PI3K/Akt and RAS/ERK signal transduction 
pathway. Given the intersection of key metabolic and proliferative pathways, it is hypothesized 
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that proteins involved in the DNA damage response and cellular growth will be impacted by 
nutrient restriction including Akt, Erk, PTEN, PCNA, and p21.  
Aim 4. Determine the impact of energy balance on markers of DNA damage and senescence in 
WT and MMTV-HER2/neu transgenic mice.  
 The molecular targets of short-term nutrient restriction determined through in vitro work 
were assessed in mammary tissue isolated from wild type and MMTV-HER2/neu transgenic 
mice exposed to chronic CR. By determining levels of key proteins and mRNA involved in DNA 
damage repair and senescence pathways in mammary tissue isolated from both cancer and 
epithelial cells, differences in response to chronic CR were determined. It is expected that tissue 
from MMTV-HER2/neu mice will have a reduction in total levels of p21 in ductal structures, 





























I. Short-term calorie restriction & MMTV-HER2/neu BC cell characteristics in vitro 
 
Murine MMTV/HER2-neu breast cancer cells were maintained in DMEM medium 
supplemented with 10% bovine cattle serum (BCS) and 5mg/ml penicillin/streptomycin. To 
mimic calorie restriction in vitro, cells were treated with medias containing reduced serum (1% 
BCS), reduced glucose (1mM Glc), or reduced serum and reduced glucose (1% BCS/1mM Glc) 
compared to control media (10% BCS/25mM Glc) (48). Cells were maintained at 37C in a 5% 
humidified chamber.  
MTT assay 
MMTV-HER2/neu cells were seeded (8x103 cells/well) in a 96-well plate overnight, 
serum and glucose restricted for 24 hours, then treated with calorie restricted medias (CON, 1% 
BCS, 1mM Glc, 1% BCS/1mM Glc) for the remaining 24 hours. Cells stained with solution 
containing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) for 3 hours, 
media aspirated, and replaced with sodium dodecyl sulfate (SDS). Plate placed on shaker for 5 
minutes and UV spectroscopy used to measure absorbance at 570 and 690 nm via the Cytation 5 
Cell Imagining reader (BioTek). Percent viability determined by the ratio of absorbance in each 
treatment group relative to control. Differences between groups assessed using one-way 
ANOVA using Turkey’s multiple comparisons tests with p<0.05 considered significant.  
Colony Formation Assay 
MMTV-HER2/neu cells were seeded (500 cells/well) in a 6-well agarose gel plate in 
triplicate corresponding to each treatment group (CON, 1% BCS, 1mM Glc, 1%BCS/1mM Glc). 
Cells were grown and monitored for 14 days, until cells treated with control media formed 
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visible colonies. Wells were imaged using EVOS FL Auto Imaging System. Number of colonies 
classified by size quantified.  
Apoptosis Assay 
 MMTV-HER2/neu cells were seeded (2.5x104 cells/well) in a 6-well plate overnight, 
serum and glucose starved for 24 hours, then treated with calorie restricted medias (CON, 1% 
BCS, 1mM Glc, 1% BCS/1mM Glc) for the remaining 48 hours. Cells prepared with the FITC 
Annexin V/Dead Cell Apoptosis Kit for Flow Cytometry (ThermoFisher) following 
manufacturer’s protocol. Phosphatidylserine (PS), a phospholipid that is translocated to the outer 
surface of the membrane upon induction of pro-apoptotic signaling, is efficiently bound by 
Annexin V, which is conjugated to fluorescein isothiocyanate (FITC), a green fluorophore, for 
detection via flow cytometry (49). Dead cells stained with propidium iodine (PI).  Samples 
processed through the Accuri 6 BD (Biosciences) and 30,000 events were recorded at 488nm 
laser excitation and emission at 530 nm and 600 nm were recorded. PI fluorescence intensity 
plotted against FITC fluorescence intensity and groups of cells categorized; live cells with 
minimal fluorescence, apoptotic cells with green fluorescence, dead cells with both red and 
green fluorescence.  
Cell Cycle Analysis 
 MMTV-HER2/neu cells were seeded (2.5x104 cells/well) in a 6-well plate overnight and 
treated with either complete or calorie restricted medias (CON, 1% BCS, 1mM Glc, 1% 
BCS/1mM Glc) for 24 hours. Cells were fixed, permeabilized, and stained with propidium 
iodide (PI) for flow cytometric analysis of cell cycle according to manufacturer’s instructions 
(Abcam). Single cell suspension run through the CyAn ADP High-Performance Flow Cytometer 
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(Beckman Coulter) and emission of PI recorded using 488nM laser excitation using. Forward 
scatter and side scatter measured on 10,000 cells and plots gated to exclude cellular debris (50).  
II. MMTV-HER2/neu Targeted Therapy and Adjunctive CR in vitro: 
Chemotherapy treatment and MTT assay 
MMTV-HER2/neu cells were seeded (2.5x103 cells/well) in a 96-well plate and grown in 
complete media for 24 hours, then treated with nutrient restricted medias (CON, 1% BCS, 1mM 
Glc, 1% BCS/1mM Glc) for 48 hours. Following the first 24 hours of nutrient restriction, cells 
were treated with sub-lethal doses of chemotherapies typically used in HER2-positive BC 
treatment regimens. Drugs were placed in media at dosages corresponding to determined IC50 
values:  5M lapatinib, 5M doxorubicin, or 500M cyclophosphamide (51-53).  
III. Molecular targets altered by nutrient stress in MMTV-HER2/neu BC cells 
Cellular Extraction and Western Blotting 
MMTV-HER2/neu cells were cultured in 100mm dishes at densities to reach 70% 
confluency after 72 hours. Once adhered, cells were treated with serum free media for 24 hours 
and corresponding calorie restricted medias for the remaining 24 hours. Whole cell lysates were 
created using RIPA lysis buffer (Sigma Aldrich) supplemented with protease inhibitor cocktail 
(Sigma Aldrich). Cells scraped from dish and incubated on ice for 20 minutes. Cellular debris 
separated via centrifugation at 14000 RPM for 15 minutes at 4C and the protein-containing 
supernatant collected.  Protein concentration determined via Bradford Assay with a Bradford 
protein quantification reagent. Equal concentrations of each protein lysate were denatured by 
boiling for 5 minutes in solution containing 2X Loading Buffer (Biorad) and 5% B-
mercaptoethanol. Protein separated via SDS-PAGE and transferred to nitrocellulose membrane 
for western immunoblotting. Membranes blocked at room temperature with gentle rocking for 1 
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hour in Tris-buffered saline containing 0.1% Tween (TBST) and 5% Bovine Serum Albumin. 
Membranes were blocked with primary antibody overnight at 4C, washed with TBST, and 
blocked in secondary antibody for 1 hour at room temperature. Chemiluminescent detection 
utilized; ECL binding substrate (Biorad) placed on membrane and imaged with the ChemiDoc 
XRS+ System (Biorad). 
IV. Animal tissue histology analysis 
 
IHC of mammary glands with anti-p21 antibody 
Whole mount slides of mammary tissue collected from female MMTV-HER2/neu 
transgenic and wild type FVB mice from a previous dietary intervention study were analyzed 
(37). Mice received either a low-fat control regimen (CON, 10 kcal% fat), a 30% calorie 
restricted (CR) regimen relative to control, or a high-fat diet induced obesity (DIO, 60 kcal% fat) 
regimen. Samples taken from both transgenic and WT mice at baseline (0 months) and 5 months 
on diet that were formalin-fixed and paraffin-embedded were analyzed via 
immunohistochemistry (IHC) staining using an anti-p21 antibody. Mammary glands were 
analyzed for positive nuclear and cytoplasmic p21 staining, quantified as ratio of positive 
staining relative to total structures.  
qRT-PCR Analysis of Mammary Tissue 
Total RNA was extracted from flash-frozen mammary tissue collected from wild type 
FVB mice at 5 months in the control and calorie restricted diet group using the RNeasy Lipid 
Tissue Mini Kit (Qiagen) following manufacturer’s protocol. RNA concentration and quality 
determined using the NanoDrop (Thermo Fisher Scientific) spectrometer. RNA suspended in 
High Capacity RNA-to-cDNA 5X Master Mix (Applied Biosystems) and reverse-transcribed in 
the Simpliamp Thermal Cycler (Thermo Fisher Scientific). cDNAs were assayed in triplicate 
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utilizing TaqMan gene probes for CDKN1A, CDKN2A, 1L6, and TP53. PCR reactions 
conducted by the ViiA 7 Real-Time PCR System (Applied Biosciences). Gene expression data 
were normalized against -actin and analyzed using the Ct method. Statistical analysis 
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Results 
I. Nutrient stress alters MMTV-HER2/neu breast cancer cell characteristics in vitro  
 
Upon culturing MMTV-HER2/neu cells in nutrient restricted medias, it was determined 
that serum restriction, not glucose restriction alone, impacts cellular viability, proliferation, 
regulation of apoptosis, and cell cycle maintenance. First, viability was assessed via MTT assay 
which measures the concentration of metabolically active cells by quantifying the amount of 
reagent that is reduced to a molecular form that is detectable through spectrophotometry. 
Following 24 hours of nutrient restriction, MMTV-HER2/neu cells cultured in reduced serum 
medias (1%BCS, 1%BCS/1mM Glc) had significantly decreased viability compared to cells 
cultured in complete media (p=0.02; p=0.03) (Figure 1). These results indicate that MMTV-
HER2/neu BC cells are sensitive to serum restriction, not to glucose restriction alone. This 
confirms the hypothesis that under conditions were protein and growth factors are limiting, 
breast cancer cells are unable to undergo sufficient reprogramming to sustain increased 
metabolic activity.  
 Next, the impact of nutrient restriction on cancer cell growth patterns and potential tumor 
characteristics were assessed by measuring colony formation. MMTV-HER2/neu cells grown for 
14 days in complete or nutrient restricted medias demonstrated differences in anchorage 
independent colony formation (Figure 2). Whole plate images were analyzed and the total 
number of colonies formed, grouped by size, were assessed. It was determined that cells cultured 
in serum restricted media had a reduced total number of colonies formed, as well as a reduced 
size of colonies present compared to control. There were no significant differences in the 
proportion of colonies formed among cell cultured in glucose restricted media. Interestingly, the 
dual serum and glucose restricted group had a total colony number comparable to control, but a 
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much larger proportion of the colonies were smaller in size than control. These results indicate 
that serum restriction has potential to alter the tumorigenic potential of HER2/neu breast cancer 
cells, confirming the hypothesis that nutrient restriction alters cell growth patterns.  
 To further examine changes in growth patterns, alterations in cell cycle regulation were 
measured in response to nutrient restriction. Apoptosis was measured using Annexin V/ 
fluorescein isothiocyanate (FITC) staining and processed via flow cytometry. Upon induction of 
apoptotic signaling, phosphatidylserine is translocated to the outer surface of the plasma 
membrane, which is efficiently bound by Annexin V conjugated to FITC for signal detection. 
Apoptotic cells experience increased Annexin V staining relative to live cells, and are 
represented as a cluster of in the upper right quadrant of the fluorescence graph (figure 3). Dead 
cells, stained with propidium iodine are represented in the third quadrant of the graph, and live in 
the first quadrant. It was determined that nutrient restriction induces apoptosis in MMTV-
HER2/neu cells. There was a significant increase in cellular apoptosis among cells cultured in 
reduced serum medias (1%BCS and 1%BCS/1mM Glc) compared to control (Figure 3). Cells 
subject to glucose restriction alone also experience a moderate shift in increased apoptosis. 
Additionally, there was a significant increase in the number of dead cells in both serum restricted 
groups. This further confirms the role of nutrient restriction in altering patters of cell cycle 
maintenance and its potential to induce apoptosis in cancer cells.  
 The impact of nutrient restriction on cell cycle regulation was further explored by 
utilizing propidium iodine staining to quantify the relative number of cells in each phase of the 
cell cycle. The proportion of propidium iodine staining correlates with the amount of DNA 
present in the cell where two copies of each chromosome (2N) characterizes non-dividing cells 
in either the G1 phase and G0, or senescent cells lacking replicative potential. Cells actively 
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replicating DNA (2N-4N) are in the S phase. Following DNA replication, cells enter G2 or M 
phase (4N) (50). Sharp peaks furthest left are characteristic of the G1/G0 phase, and shifting 
right peaks correspond to the S and G2/M phases respectively (figure 4A). Cells cultured in 
serum restricted medias experience G0/G1 arrest compared to control, which may be associated 
with increased cellular senescence. A greater proportion of glucose restricted cells were present 
in the G2/M phase compared to control and serum restricted cells. Arrest in the G2/M phase is 
characteristic of increased DNA damage which prompts cells inhibit the final steps of cell 
division.  
Figure 1. Following 24 hours of nutrient restriction, MMTV-HER2/neu cells cultured in reduced 




Figure 2.  MMTV-HER2/neu cells grown for 14 days in complete (CON) or nutrient restricted 
(1% BCS, 1mM Glc, 1% BCS/1mM Glc) medias demonstrated differences in anchorage 
independent colony formation.  
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Figure 3. MMTV-HER2/neu cells cultured in serum restricted medias for 48 hours have an 







Figure 4. Cell cycle analysis of MMTV-HER2/neu cells demonstrates that serum restriction 
induces G0/G1 arrest compared to control while glucose restriction increases the proportion of 
cells present in the G2/M phase compared to control and serum restricted cells.  
A B 
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II. Nutrient restriction sensitizes MMTV-HER2/neu cells to targeted therapy in vitro 
Finally, the efficacy of nutrient restriction as an adjunct therapy was assessed. MMTV-
HER2/neu cells cultured in nutrient restricted medias and treated with lapatinib (LP), 
doxorubicin (DXR), or cyclophosphamide (CP) and MTT assays were used to quantify cellular 
viability. It was determined that breast cancer cells cultured in serum restricted medias (1% BCS 
and 1% BCS/ 1mM Glc) and treated with lapatinib experienced decreased viability compared to 
cells cultured in control medias (p=0.030, p=0.016) (figure 8A). This provides evidence that 
serum restriction sensitizes HER2/neu BC cells to lapatinib treatment. Under the same nutrient 
restriction regimen, breast cancer cells treated with chemotherapies that inhibit DNA replication, 
DXR and CP, do not show a clear trend in changes in viability in response to therapy. DXR 
inhibits DNA synthesis by inhibiting DNA double helix ligation and thereby halting replication 
(55). CP also inhibits replication, by crosslinking DNA strands at guanine bases, forming 
inappropriate linkages, and inducing strand breakage and apoptosis (56). (B) Contrasting trends 
associated with lapatinib treatment, cells cultured in serum restricted medias and treated with 
DXR had increased viability compared to cells cultured in control media. Cells cultured in dual 
serum and glucose restricted media (1% BCS/ 1mM Glc) were significantly more viable 
compared to cells cultured in control media treated with equivalent drug doses (p=0.015). (C) 
Oppositely, cancer cells cultured in dual nutrient restricted media demonstrated reduced viability 
compared to control in response to treatment with CP (p=0.048). Contrasting trends in the 
response of cancer cells to chemotherapy following nutrient restriction may be attributed to 
differences in mechanism of action of drugs.  
 
 




Figure 8. Cellular viability assessed via MTT assays of MMTV-HER2/neu cells cultured in 
nutrient restricted medias and treated with lapatinib (LP), doxorubicin (DXR), or 
cyclophosphamide (CP). (A) Breast cancer cells cultured in serum restricted medias (1% BCS 
and 1% BCS/ 1mM Glc) and treated with lapatinib experienced decreased viability compared to 
cells cultured in control medias (p=0.030, p=0.016). (B) Cells cultured in dual serum and glucose 
restricted media (1% BCS/ 1mM Glc) and treated with DXR were significantly more viable 
compared to control (p=0.015). (C) Cells cultured in dual nutrient restricted media demonstrated 
reduced viability compared to control in response to treatment with CP (p=0.048).  
 
III. Nutrient stress alters expression of molecular targets along the PI3K/Akt signaling 
pathway 
 
Having characterized key alterations in MMTV-HER2/neu growth and maintenance 
patterns in response to nutrient restriction, the mechanisms that drive these changes were 
explored. Whole cell lysates of cells cultured in nutrient restricted medias were isolated and 
probed for specific proteins via western blotting. Antibodies for proteins that act as signaling 
molecules along the PI3K/Akt signaling pathway and that are known to modulate cell senescence 
were used to identify potential molecular targets of nutrient restriction.  
 It was determined that MMTV-HER2/neu cells cultured in serum restricted medias 
experienced decreased expression of the tumor suppressor protein, p21 and phospho-p21, 
compared to control (p=0.03; p=0.03) (figure 5A,B).  Phosphorylated p21 at Thr145 is associated 
with cytoplasmic localization of the protein, while the unphosphorylated form remains in the 
nucleus to regulate the cell cycle (57). Upstream of p21, nutrient restriction did not impact 
expression of protein kinase B (Akt), which plays in integral role in cellular survival pathways 
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by inhibiting apoptosis and inducing protein synthesis (figure 5B). Combination of serum and 
glucose restriction resulted in a modest increase in expression of the active form of the protein, 
p-Akt, relative to control (p=0.03) (figure 5E). Another key regulator of cell proliferation, the 
mitogen activated kinases, Erk and its active phosphorylated form, p-Erk were not significantly 
altered by nutrient restriction (figure 5C,F). These results indicate that p21 may be an important 
molecular target of nutrient restriction.  
Figure 5. (A, D) MMTV-HER2/neu cells cultured in serum restricted medias experienced 
decreased expression of the tumor suppressor protein, p21 and phospho-p21, compared to control 
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(p=0.03; p=0.03). (B) Short-term CR did not impact expression of protein kinase B (Akt). (E) 
Combination of serum and glucose restriction resulted in a modest increase in p-Akt expression 
compared to control (p=0.03). (E, F) Expression of Erk and p-Erk, mitogen activated kinases, are 
not significantly altered by nutrient restriction. (G) Western blotting demonstrating expression 
levels of proteins of interst relative to the housekeeping proteins B-actin and GAPDH. 
 
  
IV. Dietary energy balance modules p21 localization in vivo 
 
In order to confirm that molecular targets of nutrient restriction identified in vitro are 
similarly regulated by dietary energy balance in vivo, mammary tissue isolated from wildtype 
FVB mice and transgenic MMTV-HER2/neu mice on either high a low-fat control regimen 
(CON, 10 kcal% fat), a 30% calorie restricted (CR) regimen relative to control, or a high-fat diet 
induced obesity (DIO, 60 kcal% fat) regimen was examined. Mammary tissue was assessed for 
presence of p21 in ductal structures using IHC staining to determine if there were differences in 
protein localization. In the transgenic mouse model, lean mice on a CR diet regimen for 5 
months had less cytoplasmic p21 staining compared to CON and DIO mice and similar trends 
were mirrored in FVB tissue, although not to the same extent (figure 6). MMTV-HER2/neu mice 
on a CR regimen had significantly reduced cytoplasmic p21 levels compared to CON and DIO 
mice (p=0.03; p=0.01), this correlates with the reduced phospho-p21 expression demonstrated in 
vitro under nutrient restricted conditions.  Lean FVB mice on a CR diet regimen had reduced 
ductal p21 levels compared to mice on a DIO regimen (p=0.03) and lean MMTV-HER2/neu 
mice had significantly reduced ductal p21 compared to CON mice (p=0.045). The most 
significant trend to note from these results is the ratio of ductal p21 to cytoplasmic p21, which is 
highest in the transgenic calorie restricted mice. These demonstrates that dietary energy balance 
regulates localization of p21 in an MMTV-HER2/neu model in vivo.  
(Talk about how this lets us understand chanNext, RNA from wildtype mammary tissue 
was examined to determine the impact of calorie restriction on regulation of key molecular 
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targets in non-transformed tissue. Utilizing qRT-PCR, expression patterns for genes involved in 
senescent pathways were examined in mammary tissue isolated from lean FVB wildtype mice 
fed a CR diet and normal-weight FVB mice on a CON diet for 5 months. FVB tissue used as a 
model for normal, non-transformed mammary epithelium. Comparing CR to CON, there were no 
significant differences in gene expression patterns for CDKN1A, CDKN2A, or IL6 (p=0.31, 
p=0.92, p=0.44). CDKN1A encodes the tumor suppressor, p21, which induces senescence and 
downregulates H2AX expression through a p21-CDK-Rb pathway (58). CDK2A encodes tumor 
suppressor, p16, which participates in the initiation and maintenance of cellular senescence and 
tumor suppression (59). The IL6 gene encodes Interleukin 6 (IL6), a cytokine secreted by 
senescent cells (60). Only expression of T53, which encodes the protein p53, was reduced in CR 
mammary tissue compared to CON (p=0.0035). P53 plays a dual role in cell cycle control where 
under conditions of mild stress it activates cellular repair mechanisms, but under conditions of 
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Figure 6. IHC staining for p21 in the nucleus and cytoplasm of mammary ducts isolated from 
wildtype FVB mice (E) and from transgenic MMTV-HER2/neu mice (F). (C) MMTV-HER2/neu 
mice on a CR regimen had significantly reduced cytoplasmic p21 levels compared to CON and 
DIO mice (p=0.03; p=0.01). (B) Lean FVB mice on a CR diet regimen had reduced ductal p21 
levels compared to mice on a DIO regimen (p=0.03). (D) Lean MMTV-HER2/neu mice had 
significantly reduced ductal p21 compared to CON mice (p=0.045).  
 
Figure 7. RNA isolated from FVB analyzed utilizing qRT-PCR to compare differences in 
expression patterns between diet groups. There were no significant differences in gene 
expression patterns for CDKN1A, CDKN2A, or IL6 (p=0.31, p=0.92, p=0.44). Expression of 
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Discussion 
This study determined that short-term calorie restriction mimetics impact the viability, 
growth patterns, induction of apoptosis, and maintenance of cell cycle in MMTV-HER2/neu 
breast cancer cells. It was determined that the cells experience a differential response under 
conditions of serum restriction compared to glucose, where substantial changes in cell 
maintenance patterns were demonstrated in response to serum restriction. It was also found that 
short-term restriction also alters protein levels of key intermediates along signaling pathways 
upregulated in HER2/neu-overexpressing breast cancer. In particular, this study identified tumor 
suppressor protein p21as a potential target and provided pre-clinical evidence for the use of 
nutrient restriction as an adjunct therapy.  
 First, by mimicking short-term caloric restriction in vitro, it was determined that MMTV-
HER2/neu breast cancer cells have decreased metabolic activity under conditions of serum 
restriction compared to control (1%BCS p=0.02, 1%BCS/1mM Glc p=0.03). MTT assay that 
measured cellular viability of nutrient-restricted BC cells confirmed the hypothesis that cells are 
sensitive to an environment where proteins and growth factors in serum are not available in 
excess and respond by decreasing metabolic activity. This finding coincides with the work of 
Lamming et. al. which found that intermittent fasting and acute protein restriction inhibits tumor 
growth via decreased phosphorylation of mechanistic target of rapamycin complex 1 (mTORC1) 
in a xenograft mouse model of breast cancer (62). The IGF/mTOR pathway, which is activated 
by insulin and amino acids, plays an important role in stimulating growth and proliferation, and 
is also upregulated under conditions of diet-induced obesity (63). Further, human studies have 
demonstrated the importance of modest protein restriction in a chronic CR regimen in order to 
modulate anti-cancer effects associated with decreased IGF-1 levels (64). This highlights the 
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importance of examining the impact of caloric restriction with respect to macronutrient 
composition of dietary regimen in vivo or corresponding mimetic in vitro.  
 In addition to reduced viability demonstrated with serum restriction, this study also found 
that MMTV-HER2/neu cells grown in serum restricted medias experienced decreased anchorage 
independent colony formation. The ability of a cell to grow and divide independently of a solid 
surface is a hallmark of carcinogenesis and is used to determine if cells have undergone 
malignant transformation. This contrasts non-transformed cells, which undergo apoptosis under 
conditions where there is no surface to adhere to (65). These results demonstrate that serum 
restriction limits the growth of MMTV-HER2/neu cells in vitro.  
 Alterations in cell viability and growth can be attributed to differences in cell cycle 
regulation impacted by nutrient stress. It was found that short-term CR induces cellular apoptosis 
and necrosis in BC cells cultured in serum restricted medias. Likewise, Lee, et. al. found that 
breast cancer cells exposed to intermittent fasting (IF) conditions, a CR mimetic, had increased 
markers of DNA damage and cellular apoptosis. This group proposed that reduction of IGF-1 as 
a result of IF removed the block on apoptosis that this signaling molecule confers, and therefore 
has potential to sensitize BC cells to nutrient stress (46). Similar results were found in vivo by 
Saleh et. al. that modeled triple-negative-breast cancer and found that mice on a CR diet regimen 
had increased markers of apoptosis in tumor tissue, which was linked to downregulation of the 
IGF-1 signaling pathway (66). These findings highlight the potential of CR with protein 
restriction or IF to reduce IGF-1 levels and induce cellular apoptosis. 
Further, examination of cell cycle regulation demonstrated that serum restriction causes 
an accumulation of cells in the G0/G1 phase, and a moderate decrease of cells in the S phase 
compared to control. Serum starvation may result in cell cycle arrest through stress induction in 
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cancer cells that are unable to adapt to the loss of external growth factors by reprogramming their 
metabolism (67). This may be modulating stress-induced senescence, which occurs independent 
of telomere shortening. This explanation is limited in that multiple tests are necessary to confirm 
cellular senescence including examination of morphological changes, activation of tumor 
suppressor pathways, and increased lysosomal B-D-galactosidase activity (14). It was also 
demonstrated that a greater proportion of glucose restricted cells were present in the G2/M phase 
compared to control and serum restricted cells. Arrest in the G2/M phase is characteristic of 
increased DNA damage which prompts cells to inhibit the final steps of cell division.  
Together, these results indicate that MMTV-HER2/neu cells are sensitive to changes in 
the availability of serum-related nutrients and biological factors. This provides evidence for the 
mechanism through which caloric restriction impacts patterns of growth and progression of these 
cancer cells in vivo.  
Having defined then impact of nutrient restriction on cell cycle regulation, it was posited 
that these mechanisms would act synergistically with chemotherapies to increase the sensitivity 
of breast cancer cells to drug treatment. Several rodent in vivo studies have demonstrated that 
short-term food starvation sensitizes cancer cells to chemotherapies in mouse models of lung, 
breast, and pancreatic cancer (39,40,47). However, this relationship has only been explored for 
HER2/neu breast cancer in vitro, highlighting the importance of this work. This study 
demonstrated that HER2/neu cells cultured in serum restricted medias had increased sensitivity 
to treatment with the tyrosine kinase inhibitor, lapatinib (LP). This finding is in agreement with 
the work of Caffa et. al. which demonstrated that four-day starvation of the HER2-
overexpressing human cell line, SKBR3, acted synergistically with lapatinib. This finding was 
rationalized with the hypothesis that inhibition of MAPK signaling by nutrient restriction blocks 
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the compensatory mechanisms along the PI3K/Akt pathway that limit the efficacy of TKIs and 
confer therapeutic resistance (68). These findings support the development an in vivo model of 
HER2-overexpressing BC combing short-term fasting with lapatinib treatment, or other targeted 
therapy. Further exploration is needed to determine which genes are differently expressed in 
response to short-term fasts in oncogene driven breast cancer. A major limitation of this current 
work is the lack of mechanistic relationship between serum starvation and lapatinib sensitivity in 
HER2/neu cells. Future work will explore differences in expression of protein and RNA along 
the MAPK signaling pathway. Additionally, if an in vivo model to test this hypothesis were to be 
developed, several cycles of chemotherapy with short-term starvation would need to be 
incorporated to explore whether or not cancer cells are able to acquire metabolic alterations to 
evade downregulation of proliferative pathways under nutrient restricted conditions. 
There were less clear trends found when nutrient restriction was combined with non-
specific chemotherapy treatment in HER2/neu BC cells. Nutrient restricted cells treated with 
doxorubicin (DXR) had increased viability compared to control, opposing the proposed 
hypothesis. While greater exploration of the mechanism underlying this relationship is necessary, 
including cell cycle analysis and apoptosis assays, it is plausible that reduction of mTORC1 
activity in response to nutrient restriction results in decreased p70S6 kinase (S6K) activation, 
which negatively regulates IRS-1 to block activation of Akt. Under conditions where mTORC1 
is reduced, Akt activity increases as a compensatory mechanism to promote growth (69). 
Therefore, metabolic activity may be elevated to compensate for this nutrient restricted 
environment.  
However, nutrient restriction demonstrated a synergistic effect with cyclophosphamide 
(CP) treatment.  The mechanism of CP results in increased apoptosis of cells, which corresponds 
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to trends demonstrated by nutrient restriction alone, which may modulate the synergism. Future 
work is needed to elucidate this relationship including apoptosis assays and cell cycle analysis to 
confirm this hypothesis. These findings are in agreement with several studies which 
demonstrated that modeled stress-sensitization in different cancer cell lines, including a 
metastatic triple negative cell line that experienced increased oxidative stress, caspase 3 
cleavage, and apoptosis in response to short-term starvation with chemotherapy treatment (46).  
One limitation of these experiments was a lack of comparison between cancer cells and 
normal epithelial cells in response to chemotherapy treatment. Literature by the Longo 
laboratory has suggested that cells experience a differential stress response whereby normal cells 
enter a quiescent, chemo-protective state in response to nutrient stress, unlike cancer cells that 
maintain proliferative activities and are rendered more susceptible to chemotherapy. Future work 
will repeat glucose and serum restriction experiments in MCF10A, a human breast epithelia cell 
line to determine if this hypothesis is valid under these cell culture conditions. 
Next, protein levels of key intermediates along the PI3K/Akt and Ras/Erk pathways were 
assessed following short-term calorie restriction to determine where along these axes nutrient 
stress impact cellular growth and proliferation patterns. Examination of intermediates along key 
signaling pathways revealed alternations in protein level of p-Akt and p-Erk.  It is plausible that 
restriction of glucose modulates increased activation of Akt due to the role this molecule plays in 
regulation of glucose transporters. Under conditions where intracellular close levels are 
diminished in response to restriction, activation of Akt has potential to increase transcription of 
glucose transporters to alleviate the stress. Further, trending increases of the active form of Erk, 
p-Erk, which is involved in cell proliferation pathways was found under conditions of serum 
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restriction. This may indicate a compensatory mechanism for cells to maintain proliferative 
activities under conditions of reduced protein and growth factor availability. 
 Interestingly, it was discovered that serum restriction targets tumor suppressor protein 
p21 along the PI3K/Akt signaling pathway. MMTV-HER2/neu cells cultured in serum restricted 
medias experienced decreased expression of the tumor suppressor protein, p21 and phospho-p21, 
compared to control (p=0.03; p=0.03). These results coincide with the observed cell cycle arrest 
that occurs in response to serum restriction. The unphosphorylated form of p21 is concentrated in 
the nucleus where it acts as a cyclin dependent kinase inhibitor (CKI) and induces cell cycle 
arrest in response to DNA damage through p53 activation. It achieves this by binding PCNA, 
which is necessary for DNA replication (70). Conversely, proliferative activities of p21 are 
promoted when it is re-localized to the cytoplasm. This is achieved by phosphorylation at 
threonine 145 (T145) by Akt, a key regulator of proliferation and survival in the P13K signaling 
pathway downstream of HER2.  T145 phosphorylation disrupts hydrogen bonding patterns 
between p21 and PCNA, destabilizing this complex, and preventing cell cycle inhibition. 
Additionally, cytoplasmic subcellular localization prevents any binding interaction with PCNA.  
Further, cytoplasmic p21 is able to resist apoptosis by binding and inhibiting ASK1 and 
procaspase 3, pro-apoptotic regulators (70). Reduction in phospho-p21 achieved by nutrient 
restriction may provide a mechanistic explanation for increased apoptosis and G0/G1 cell cycle 
arrest observed in vitro.  Interpretation of these results is limited in that T145 phosphorylation is 
not a definitive marker of subcellular localization.  
Further research is needed to examine the precise mechanisms by which serum restriction 
reduces levels of p21, and how this may impact regulation of key tumorigenic and senescent 
pathways. Based on previous work by Yaglom, et. al., it was determined that nuclear p21 plays a 
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role in reducing expression of a major DNA repair histone H2AX via inhibition of CDK4 
phosphorylation activity which activates Rb upstream of H2AX. H2AX is involved in double 
strand break repair, and when its levels are decreased, it is posited that cancer cells have 
increased sensitivity to chemotherapeutic regimens that target these repair mechanisms (56). The 
findings of this study that serum restriction decreases expression of p21 may indicate an 
important mechanistic driver of the anti-tumorigenic effect of conferred by calorie restriciton in 
MMTV-HER2/neu transgenic mice. 
Ongoing work is being completed where HER2/neu cells are transiently transfected with 
plasmids that overexpress p21 in either the nucleus or the cytoplasm. We hypothesize that in 
cells that constitutively overexpress p21 in the cytoplasm, serum restriction will not mediate 
changes in cell growth and proliferation patterns that are normally conferred by serum 
restriction. Additionally, experiments are ongoing where cells are transfected with plasmids that 
express a short-hairpin RNA that constitutively destroys p21 mRNA, preventing its expression. 
This experiment will provide information on whether or not p21 is the major molecular target of 
nutrient restriction. We hypothesize that in cells that that have p21 reduced, there anti-
proliferative alterations modulated by nutrient restriction under wildtype conditions will not 
occur. 
 Finally, we examined preserved mammary tissue from mice stained for p21 to determine 
if the mechanisms demonstrated by short-term CR in vitro were similarly impacted by long-term 
CR in vivo. This study found that lean MMTV-HER2/neu transgenic mice on a caloric 
restriction diet had significantly decreased cytoplasmic p21 levels compared to normal mice fed 
a control diet and obese mice fed a DIO diet. Importantly, the ratio of cytoplasmic p21 to nuclear 
p21 was reduced in the calorie restricted mice. This provides evidence for the hypothesis that 
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calorie restriction regulates p21 localization. Further, this coincides with in vitro data 





 This study provide evidence that short-term calorie restriction drives alterations in 
MMTV-HER2/neu breast cancer cell signaling pathways and subsequently in cell growth and 
maintenance patterns. HER2/neu breast cancer cells experience a differential response to glucose 
and nutrient restriction and have increased sensitivity to the therapies lapatinib and doxorubicin 
under conditions of serum restriction. Restriction of serum alters expression of tumor suppressor 
protein p21 in vitro and decreases the proportion of cytoplasmic to nuclear p21 in vivo, 
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